LIVE
A once-weekly 39-amino-acid triple agonist of the GLP-1, GIP, and glucagon receptors (CAS 2381089-83-2), developed by Eli Lilly as LY3437943. Adds glucagon-receptor activity on top of the GLP-1/GIP mechanism of tirzepatide to drive additional energy expenditure. Phase 3 TRIUMPH program reported 28.7% mean body-weight reduction at 12 mg over 68 weeks in obesity with knee osteoarthritis — the highest Phase 3 figure on record for an obesity agent. NDA submission planned for 2026; not yet FDA-approved. Sold by research vendors under codes including GLP3-R, Reta, R-30.
For research purposes only. Not medical advice.
Step One currently lists Retatrutide at $2.58/mg, the lowest indexed price across 22 tracked research peptide vendors.
Retatrutide ranges from $2.00/mg to $12.00/mg across 113 listings from 22 research peptide vendors, normalized to USD per milligram and refreshed daily.
22 research peptide vendors currently list Retatrutide on PeptideScouter. We track 113 active listings across size and kit variants.
Retatrutide's CAS Registry Number is 2381089-83-2. It is also sold as GLP3-R, GLP3-Reta, R-30.
